| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ephrin-A receptor (EphA3) kinase[1][2]
AWL-II-38.3 targets Ephrin type-A receptor 3 (EphA3) kinase. The structure of AWL-II-38.3 fits into the ATP-binding and substrate-binding pockets of EphA3. It forms four direct hydrogen bonds with the ATP-binding cleft of EphA3, interacting with key residues such as Met702, Thr699, Asp764, and Glu670. By inhibiting EphA3 kinase activity, AWL-II-38.3 can modulate signaling pathways involved in cell migration, axon guidance, and angiogenesis. |
|---|---|
| ln Vitro |
LIMK2 and LIMK1 ATP-binding and substrate-binding pockets are fitted by AWL-II-38.3[2].
In vitro, AWL-II-38.3 is a highly potent EphA3 inhibitor with potent kinase inhibitory activity. It does not exhibit significant cellular activity against Src family kinases or b-raf. This selectivity makes it a valuable tool for studying EphA3-specific functions. |
| ln Vivo |
In vivo, AWL-II-38.3 can be used to study the role of EphA3 in various biological processes, including cell proliferation, differentiation, and survival. It has potential applications in cancer research, as EphA3 is overexpressed in some tumors. However, specific in vivo activity data are not detailed in the search results.
|
| Enzyme Assay |
Non-cellular assays for AWL-II-38.3 involve measuring its inhibitory activity against EphA3 kinase using recombinant EphA3 protein in an in vitro kinase assay. The assay measures the phosphorylation of a peptide substrate in the presence of ATP, and the inhibition of this activity is used to determine the IC₅₀ value. Selectivity profiling against a panel of other kinases can also be performed.
|
| Cell Assay |
Cell-based assays for AWL-II-38.3 involve studying its effects on EphA3 signaling in cells. Cells expressing EphA3 can be treated with the compound, and the phosphorylation of downstream signaling molecules can be assessed by Western blot. The effects on cell proliferation, migration, and survival can also be measured.
|
| Animal Protocol |
In vivo animal experiments with AWL-II-38.3 would typically involve administering the compound to mice or rats to study its effects in disease models. Xenograft models of cancer could be used to evaluate its anti-tumor efficacy. Pharmacokinetic and toxicity studies would also be conducted to assess its suitability for further development.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for AWL-II-38.3 have not been extensively reported. The compound is soluble in DMSO at 80 mg/mL. It can be formulated for in vivo use in 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline at 10 mg/mL.
|
| Toxicity/Toxicokinetics |
No specific toxicity data have been reported for AWL-II-38.3. As a research compound, it should be handled with standard laboratory safety precautions. Its safety profile has not been evaluated for human use.
|
| References |
[1]. Yongmun Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4467-70.
[2]. Efrat Mashiach-Farkash, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012 Jun;3(6):629-39. |
| Additional Infomation |
N-[2-methyl-5-[[[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-oxymethyl]amino]phenyl]-5-isooxazolamide is one of the benzamide compounds.
AWL-II-38.3 is a research compound, not an approved drug. It is a highly potent and selective EphA3 kinase inhibitor, used as a chemical probe to study the role of EphA3 in cellular processes. The compound is not intended for human therapeutic use. |
| Molecular Formula |
C23H18F3N5O3
|
|---|---|
| Molecular Weight |
469.41593503952
|
| Exact Mass |
469.136
|
| CAS # |
1135205-94-5
|
| PubChem CID |
24880028
|
| Appearance |
White to light yellow solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
739
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC(=O)C4=CC=NO4
|
| InChi Key |
IYUFHBXMTTXZBE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H18F3N5O3/c1-13-3-4-17(10-19(13)30-22(33)20-5-6-28-34-20)29-21(32)15-7-16(23(24,25)26)9-18(8-15)31-11-14(2)27-12-31/h3-12H,1-2H3,(H,29,32)(H,30,33)
|
| Chemical Name |
N-[2-methyl-5-[[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)benzoyl]amino]phenyl]-1,2-oxazole-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 66.67 mg/mL (142.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1303 mL | 10.6514 mL | 21.3029 mL | |
| 5 mM | 0.4261 mL | 2.1303 mL | 4.2606 mL | |
| 10 mM | 0.2130 mL | 1.0651 mL | 2.1303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
